Long-acting pharmacotherapies targeting incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity Terns plans to initiate a Phase 2 clinical trial ...

MONDAY, Nov. 11, 2024 (HealthDay News) -- The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart ...

This study presents valuable insights into the organization of second-order circuits for gustatory neurons, particularly how they integrate opposing taste inputs and the metabolic states that regulate ...